DICE Therapeutics is developing transformative medicines for autoimmune and inflammatory diseases. It designs and develops innovative oral medicines targeting biologically validated immunology targets.

DICE Therapeutics

Domain Not Resolving

Amazon

Microsoft Exchange Online

DMARC

Office 365 Mail

Microsoft Azure DNS

Amazon Virginia Region

AWS Global Accelerator

COVID-19

Chief Scientific Officer

John Jacobsen

Kevin Judice

Chief Medical Officer

Tim Lu

Vice President Clinical Development

Jeffrey Enejosa

Engineering

Mike Schwaebe

VP, Finance

Oliver Yasbek

Vice President, Medicinal Chemistry

Paul Fatheree

Vice President Regulatory

Paula Opal

Associate Director, Regulatory Affairs CMC

Andrew Lui

Operations

Christianne Parotti

Jake Simson

Founder and Chief Executive Officer

Nick Shah

Head of In Vitro Pharmacology

Western US Companies With More Than 10 Employees (Top 10K)

San Francisco Companies With Less Than $50M in Revenue (Top 10K)

Medical Device Companies With Less Than $500M in Revenue (Top 10K)

West Coast Acquired Companies With Less Than $1B in Revenue

DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. 

The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Post-IPO Equity - Dice Therapeutics

RA Capital Management

Sands Capital Ventures

Series C - Dice Therapeutics

Northpond Ventures

Series B - Dice Therapeutics

Venture Round - Dice Therapeutics

Miller Investment Management

Private Equity Round - Dice Therapeutics

Computer and Software Services and Scientific Services

San Francisco

California

United States

North America

Dice Therapeutics

DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Global BMI Index

The Week in Press Releases: 13 Stories You Need to See

Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?

PayPal-KKR deal, Alibaba shares fall, Eli Lilly-Dice Therapeutics deal: Trending tickers

DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday

Analyst Expectations for DICE Therapeutics's Future

Why DICE Therapeutics Stock Is Soaring Tuesday

Lilly makes fresh bet on IL-17 with $2.4B acquisition of Dice Therapeutics

Eli Lilly to Acquire DICE Therapeutics for $2.4 Billion

An oral small molecule inhibitor targeting IL-17 for the treatment of psoriasis and other autoimmune diseases.

A small molecule inhibitor of IL-17 with potentially improved potency and metabolic stability for autoimmune diseases.

A program to identify compounds with increased structural diversity targeting IL-17 for autoimmune diseases.

Small molecule inhibitors targeting α4β7 for the treatment of inflammatory bowel disease.

Small molecule inhibitors targeting αVβ1 and αVβ6 for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases.

Small molecule inhibitors of PD-L1 for the treatment of various cancers.

India

Asia

France

Europe

Macedonia

Pakistan

HTML5

jQuery

Google Compute Engine

Google Maps API

Fonts.com

Google Tag Manager

Microsoft Outlook

GoDaddy Premium DNS

Google Fonts

Google Analytics

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 17, 2024 6:31 AM	67196022
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 17, 2024 6:31 AM	fe1cf505
crunchbase trigger	general	Nov 22, 2024 7:44 AM	b4081e4f
crunchbase profile	general	Nov 23, 2024 2:59 AM	671064e6
li profile	general
translate crunchbase fundingrounds	general	Nov 23, 2024 3:41 AM	7d542c8a
peers	general	Oct 17, 2024 6:31 AM	900ef2e9
news basic	general	Oct 17, 2024 6:31 AM	dae96583
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:DICETHERAPEUTICS

DICE Therapeutics